BRYAN JOHNSON

Bryan Johnson stands as a prominent figure in the venture capital landscape, known for his visionary approach to investing in deep technology and frontier science. As a General Partner at OS Fund, he plays a pivotal role in identifying and nurturing companies poised to make a significant impact on humanity's future. His investment philosophy is deeply rooted in his entrepreneurial background and a profound commitment to advancing human capabilities and solving complex global challenges.

At OS Fund, Bryan Johnson's focus areas are expansive and forward-thinking. He actively seeks out opportunities in biotechnology, artificial intelligence, neurotechnology, and longevity. The fund's mandate, and Bryan's personal interest, extends to human augmentation and other deep tech sectors that promise to redefine the boundaries of what's possible. He is particularly drawn to ventures that leverage scientific breakthroughs to create tangible, transformative solutions, whether in health, computation, or fundamental human experience.

Johnson's career background provides a robust foundation for his investment acumen. Before his tenure at OS Fund, he achieved remarkable success as a serial entrepreneur. He founded Braintree, a leading payment processing company, which was acquired by PayPal for an impressive $800 million. This experience not only honed his business development skills but also instilled in him a deep understanding of scaling innovative technologies. Following Braintree, Johnson founded Kernel, a neurotechnology company dedicated to developing advanced brain interfaces to improve human cognition and address neurological conditions. His most recent public endeavor, Project Blueprint, showcases his personal dedication to longevity and optimizing human health through rigorous scientific protocols, further cementing his expertise and passion in the biotech and health sectors.

Through OS Fund, Bryan Johnson has been instrumental in backing companies that align with his vision for a technologically advanced future. While specific individual investments are part of the fund's broader portfolio, OS Fund has a track record of supporting groundbreaking firms such as Ginkgo Bioworks, a leader in synthetic biology, and Recursion Pharmaceuticals, which uses AI to accelerate drug discovery. These examples illustrate the caliber of companies that benefit from Johnson's strategic insight and the fund's capital. His involvement goes beyond mere funding; he brings a founder's perspective, mentorship, and a vast network to the entrepreneurs he supports, helping them navigate the complexities of bringing revolutionary technologies to market. Bryan Johnson's work at OS Fund is not just about financial returns; it's about investing in the very fabric of tomorrow's world.